{"id":164265,"date":"2026-11-22T04:53:31","date_gmt":"2026-11-22T04:53:31","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/164265\/"},"modified":"2026-11-22T04:53:31","modified_gmt":"2026-11-22T04:53:31","slug":"roche-pauses-future-germany-investments","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/164265\/","title":{"rendered":"Roche pauses future Germany investments"},"content":{"rendered":"<p>Amid tensions over government healthcare cost-cutting policies, Roche has slammed the brakes on new investments in Germany, joining an expanding group of drugmakers pulling back from the European country.<\/p>\n<p>Speaking with the German newspaper Die Welt, Daniel Steiners, head of Roche Germany, said that the company has \u201cput all future investment decisions in Germany on hold for the time being,\u201d according to Reuters.<\/p>\n<p>Roche paused future investments in Germany this summer, a Roche spokesperson told Fierce, pointing to a report in August by the <a href=\"https:\/\/www.ft.com\/content\/8891d59f-f4e0-4f81-bfae-b686cd1c4d98?syn-25a6b1a6=1\" rel=\"nofollow noopener\" target=\"_blank\">Financial Times<\/a>.\u00a0<\/p>\n<p>Steiners blamed the country\u2019s recent <a href=\"https:\/\/www.fiercepharma.com\/pharma\/germany-pushes-through-healthcare-reform-package-despite-pharmas-drug-discount-resistance\" rel=\"nofollow noopener\" target=\"_blank\">healthcare reform plan<\/a> that intends to cut drug prices further, asserting that the move has \u201crecently destroyed a lot of trust.\u201d<\/p>\n<p>The controversy centers on legislative measures designed to cap statutory health insurance spending by enforcing deeper discounts on branded medicines. A previously proposed variable rebate mechanism was <a href=\"https:\/\/www.fiercepharma.com\/pharma\/germany-backs-plan-install-variable-discount-pricing-drugs\" rel=\"nofollow noopener\" target=\"_blank\">scrapped<\/a> following heavy industry criticism, but a higher fixed rebate, from 7% to 15.5%, will be implemented in 2027.<\/p>\n<p>According to Roche, Berlin\u2019s reliance on quick-fix budget cuts rather than structural healthcare reform places an unfair burden on the biopharma industry and sends a negative signal to companies seeking to invest in Germany.\u00a0<\/p>\n<p>Germany has announced plans to introduce a site-exemption clause that would allow companies to reduce or waive the additional rebate if they meet certain national footprint and investment criteria. Steiners argued that the term only partially offset the negative effects of the legislation, and that Germany needs a more comprehensive strategy, according to Reuters.<\/p>\n<p>The exemption clause \u201crepresents the final opportunity to restore confidence in Germany as a competitive and reliable investment location,\u201d the Roche spokesperson said. \u201cHowever, such a clause will only be credible if it forms part of a broader economic policy agenda that rewards innovation, [a] provides predictable framework conditions for investment and restores Germany&#8217;s international competitiveness.\u201d<\/p>\n<p>The spokesperson noted that the proposal is advancing but has yet to become law.<\/p>\n<p>Roche has created more than 1,800 new jobs in Germany since 2020 and invested approximately 3.8 billion euros, the spokesperson pointed out. Among the Swiss pharma\u2019s existing investments in Germany is a 600 million euro commitment for a diagnostic facility in Penzberg. The company told Fierce in June that it <a href=\"https:\/\/www.fiercebiotech.com\/medtech\/roche-will-continue-eu600m-diagnostics-investment-germany-warns-future-risk\" rel=\"nofollow noopener\" target=\"_blank\">would not withdraw<\/a> that investment amid controversies over Germany\u2019s new drug pricing rules.\u00a0<\/p>\n<p>The spokesperson did not respond to Fierce\u2019s question about whether the paused investment decisions encompass R&amp;D, such as new clinical trials and business development for new innovations.\u00a0<\/p>\n<p>Germany, long regarded as a premier location for European life sciences R&amp;D, manufacturing and commercialization, is facing dwindling investment from the biopharma industry.\u00a0<\/p>\n<p>Domestic drugmaker BioNTech is <a href=\"https:\/\/www.fiercepharma.com\/pharma\/biontech-close-sites-germany-singapore-after-failed-buyer-search\" rel=\"nofollow noopener\" target=\"_blank\">shutting down<\/a>\u00a0three local facilities, putting 1,800 jobs at risk, although that decision is more related to the company\u2019s own post-pandemic right-sizing than the government\u2019s health policy.\u00a0<\/p>\n<p>Meanwhile, GSK is <a href=\"https:\/\/www.fiercepharma.com\/manufacturing\/gsk-makes-difficult-decision-shutter-german-flu-vaccine-manufacturing-site\" rel=\"nofollow noopener\" target=\"_blank\">closing<\/a> a legacy egg-based flu vaccine manufacturing site in Dresden, citing dwindling demand. But the British pharma\u2019s choosing another Canadian site\u00a0over the German site for the same function is telling.\u00a0<\/p>\n<p>In pullbacks directly attributed to the tightening policy environment, Eli Lilly earlier this year decided to <a href=\"https:\/\/www.fiercepharma.com\/pharma\/lilly-boehringer-plan-slash-investment-germany-report\" rel=\"nofollow noopener\" target=\"_blank\">halve<\/a> its planned 2.3 billion-euro investment in Germany, while German company Boehringer Ingelheim cut its domestic spending by 900 million euros.\u00a0<\/p>\n<p>Around the same time, Pfizer CEO Albert Bourla said his company was also <a href=\"https:\/\/www.fiercepharma.com\/pharma\/amid-growing-industry-backlash-germanys-healthcare-reform-plan-pfizer-ceo-bourla-re\" rel=\"nofollow noopener\" target=\"_blank\">reassessing<\/a> its investments in Germany, suggesting that the policy reforms call into question the market\u2019s predictability required for long-term pharma investments.<\/p>\n<p>Novartis CEO Vas Narasimhan has also expressed deep disappointment over the cost-cutting measures, calling them \u201ca significant setback to rewarding innovation in Germany,\u201d and \u201ca strong negative signal to the global biopharmaceutical industry that Germany does not view our industry as a strategic sector.\u201d<\/p>\n<p>\u201cI think it will lead to changes in the investment environment in Germany going forward,\u201d he said.<\/p>\n<p>Large pharma companies are cutting back in Germany as the Trump administration is ramping up political pressure on drugmakers to onshore investments in the U.S. while pushing for higher drug spending by foreign countries. The Office of the United States Trade Representative recently <a href=\"https:\/\/www.fiercepharma.com\/pharma\/us-investigate-germanys-proposed-drug-spending-reforms\" rel=\"nofollow noopener\" target=\"_blank\">launched<\/a> a Section 301 investigation into what it called \u201cpersistent underpayment\u201d for medicines in Germany.\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"Amid tensions over government healthcare cost-cutting policies, Roche has slammed the brakes on new investments in Germany, joining&hellip;\n","protected":false},"author":2,"featured_media":164266,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[41939,1344,2536,134],"class_list":["post-164265","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-fierce-pharma-homepage","tag-germany","tag-pharma","tag-roche"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117658308158319796","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/164265","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=164265"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/164265\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/164266"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=164265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=164265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=164265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}